Skip to main content

Table 2 CD4 cell count assessment, enrolment into care and treatment and ARV initiated during pregnancy among HIV positive women according to the type of HIV services package, Rwanda, from January through December 2008

From: Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens

  Full package$ Stand-alone RR (95% CI) #
Sites, N (%) 18 (56%) 14 (44%) -
Total HIV positive pregnant women (N) 743 195 -
CD4 cell count assessment, N (%):    
   Screened for CD4 cell counts 547 (74%) 111 (57%) 1.3 (1.1 - 1.4)
   Received CD4 cell count result¶¶ 536 (98%) 111 (100%) 0.97 (0.96 - 1.0)
   CD4 cell count < 350 cells/mm3 134 (25%) 26 (23%) -
Enrolment into care and treatment, N (%) 495 (67%) 69 (35%) 1.9 (1.5 - 2.3)
HAART initiation among women with CD4 cell counts < 350 cells/mm3, N (%) 105 (78%) 22 (85%) 0.9 (0.7 - 1.1)
Received PMTCT prophylaxis or
more efficacious ARV regimens:
511 (96%) 106 (100%) 0.9 (0.9 - 1.0)
   Dual (AZT/sd-nvp) prophylaxis 331 (62%) 72 (68%) -
   HAART for life 105 (20%) 22 (21%) -
   Short-course HAART 75 (14%) 12 (11%) -
sd-nvp only 21 (4%) 0 (0%) -
  1. $ Full package sites provide comprehensive PMTCT and on-site ART services.
  2. The number of HIV+ pregnant women who underwent the CD4 test, including women tested in ANC and those of known HIV+ status who had not initiated HAART before their current pregnancy.
  3. ¶¶ The number of HIV+ women receiving CD4 results in a given quarter, including all women who received their results at a follow-up visit during the quarter. This number includes women tested in previous quarters who retrieved their CD4 counts during the indicated quarter.
  4. # Relative Risk (RR) comparing the full package service (PMTCT and ART) as a reference to the stand-alone service; CI: confidence interval.